Teradyne price target lowered to $69 from $81 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Teradyne (TER) to $69 from $81 and keeps an Underweight rating on the shares. Teradyne revised its 2025 and 2026 guidance at the company’s analyst day on March 11, but the firm still thinks those forecasts are “too optimistic,” the analyst tells investors. The firm notes that its own revised 2025-2026 revenue forecasts are7% and 18% below company expectations and 6% and 12% below the Street, respectively. The firm believes the earnings release on April 28 and associated call on April 29 provides a “good opportunity for the company to retract both 2025-2026 guides and reset aggressive street expectations,” the analyst added.